Fibrates and microvascular complications in diabetes - Insight from the FIELD study

Current Pharmaceutical Design

Volumn 15, Issue 5, 2009, Pages 537-552

  Ansquer, Jean Claude ^a   Foucher, C ^a   Aubonnet, P ^b   Le Malicot, K ^a  

^a Laboratoires Fournier SA   (France)

^b Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Diabetes; Fenofibrate; Fibrates; Nephropathy; Neuropathy; Retinopathy

Indexed keywords

ATROMID; BEZAFIBRATE; C REACTIVE PROTEIN; CLOFIBRATE; CREATININE; ETOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GEMFIBROZIL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; ANTILIPEMIC AGENT; CLOFIBRIC ACID;

ALBUMINURIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD CLOT LYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG TARGETING; DYSLIPIDEMIA; GENE TARGETING; GENETIC SUSCEPTIBILITY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; RETINA EXUDATE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; TRANSCRIPTION INITIATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CARDIOVASCULAR DISEASE; DIABETIC ANGIOPATHY; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CLOFIBRIC ACID; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; HUMANS; PROCETOFEN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 64749088854     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787315701     Document Type: Review

References (158)

1. Keating GM, Croom KF. Fenofibrate: A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007; 67: 121-53.
2. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (The FIELD study): Randomised controlled trial. Lancet 2005; 366: 1849-61.
3. Keech AC, Mitchell P, Summanen PA, O'Day JO, Davis TME, Moffitt MS, et al. Effect of fenofibrate on the ned for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 2007; 370: 1687-97.
4. Burgess D, Hunt D, Li L, Zhang J, Sy R, Laakso M, et al. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Circulation 2007; 116: II_838.
5. Fitzgerald D. The discovery of the fibrates. Dialogues Cardiovasc Med 2003; 8: 3.
6. Robillard R, Fontaine C, Chinetti G, Fruchart JC, Staels B. Fibrates. Hand Exp Pharmacol 2005; 170: 389-406.
7. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347: 645-50.
8. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, et al. PPAR α and PPAR β activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15: 5336-48.
9. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator- activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997; 8: 159-66.
10. Vu-Dac N, Gervois P, Jakel H. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator- activated receptor... activators. J Biol Chem 2003, 278: 17982-85.
11. Prieur X, Coste H, Rodriguez JC. The human apolipoprotein AV gene is regulated by PPAR.. and contains a novel FXR response element. J Biol Chem 2003; 278: 25468-80.
12. Staels B, Vu-Dac N, Kosykh V, Saladin R, Fruchart JC, Dallongeville J, Auwerx J. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. J Clin Invest 1995; 95: 705-12.
13. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994, 269: 31012-8.
14. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995, 96: 741-50.
15. Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, et al. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol 2005; 25: 585-91.
16. Birjmohun RS, Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45: 185-97.
17. Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. Fibrates: What have we learned in the past 40 years? Pharmacotherapy 2007; 27: 412-24.
18. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45.
19. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Mahmood S, Richmond W, et al. Cardiovascular outcomes in type 2 diabetes: A double-blind placebo-controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 21: 641-8.
20. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21-7.
21. Despres J-P, Lemieux I, Salomon H, Delaval D. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: A 12- week randomized trial. J Intern Med 2002; 251: 490-9.
22. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalises the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996; 16: 763-72.
23. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-5.
24. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8.
25. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs highdensity lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597-604.
26. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: Randomised controlled trial. BMJ 2002; 325: 1139.
27. de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A. Secondary preventive potential of lipid-lowering drugs: The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 1996; 17: 37-42.
28. Frick MH, Syvänne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, et al. Lopid Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic progression of coronary and vein-graft therosclerosis by gemfibrozil after coronary bypass surgery in men with low evels of HDL cholesterol. Circulation 1997; 96: 2137-43.
29. DAIS Investigators. Effect of fenofibrate on progression of coronary- artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-10.
30. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc Res 2001; 52: 290-8.
31. Chew GT, Watts GF, Davis TM, Stuckey BG, Beilin LJ, Thompson PL, et al. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 2008; 16. Epub ahead of print
32. Barbier O, Pineda Torra I, Dugay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator- activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 717-26.
33. Chinetti-Gbaguidi G, Fruchart JC, Staels B. Pleiotropic effects of fibrates. Curr Atheroscler Rep 2005; 7: 396-401.
34. Tsimihodimos V, Kostoula A, Kakafika A, Bairaktari E, Tselepis AD, Mikhailidis DP, et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 2004; 9: 27-33.
35. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis J Clin Invest 2006; 116: 571-80.
36. Dragomir E, Tircol M, Manduteanu I, Voinea M, Simionescu M. Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced high glucose concentration in human endothelial cells. Vascul Pharmacol 2006; 44: 440-9.
37. Okopień B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006; 91: 1770-8.
38. Chapman MJ. Fibrates in 2003: Therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003; 171: 1-13.
39. Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: The DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006; 48: 396-401.
40. Tsimihodimos V, Kakafika A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 2003; 44: 927-34.
41. Achimastos A, Liberopoulos E, Nikas S, Bairaktari E, Miltiadous G, Tsimihodimos V, et al. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. Curr Med Res Opin 2002; 18: 59-63.
42. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
43. CDC National Health Interview Survey (NHIS) Early Release of Selected Estimates Based on Data From the January-September 2007 National Health Interview Survey
44. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, et al. The burden of mortality attributable to diabetes: Realistic estimates for the year 2000. Diabetes Care 2005; 28: 2130-5.
45. Fowler MJ. Microvascular and Macrovascular Complications of Diabetes. Clinical Diabetes 2008; 26: 77-82.
46. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, et al. Incidence of coronary heart disease in type 2 diabetic men and women: Impact of microvascular complications, treatment, and geographic location. Diabetes Care 2007; 30: 1241-7.
47. Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY. Diabetic retinopathy and the risk of coronary heart disease. The Atherosclerosis Risk in Communities Study. Diabetes Care 2007a; 30: 1742-6.
48. Cheung N, Rogers S, Couper DJ. Is diabetic retinopathy an independent risk factor for ischemic stroke? Stroke 2007; 38: 398-401.
49. Targher G, Bertolini L, Zenari L, Lippi G, Pichiri I, Zoppini G, et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Med 2008; 25: 45-50.
50. Cheung N, Wang JJ, Rogers SL, Brancati F, Klein R, Sharrett AR, et al. Diabetic retinopathy and risk of heart failure. J Am Coll Cardiol 2008; 51: 573-8.
51. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care 2007; 30: 292-9.
52. Prevention of blindness from Diabetes Mellitus. Report of a WHO consultation in Geneva, 9-11 November 2005. WHO Library Cataloguin- in-publication Data
53. Davidson JA, Ciulla TA, McGill JB, Kles KA, Anderson PW. How the diabetic eye loses vision. Endocrine 2007; 32: 107-16.
54. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. Retinopathy in diabetes. Diabetes Care 2004; 27: S84-S87.
55. Morello CM. Etiology and natural history of diabetic retinopathy: An overview. Am J Health Syst Pharm 2007; 64: S3-7.
56. Kastelan S, Zjacić-Rotkvić V, Kastelan Z. Could diabetic retinopathy be an autoimmune disease? Med Hypotheses 2007; 68: 1016-8
57. Dodson P. Diabetic retinopathy: Treatment and prevention. Diabetes Vasc Dis Res 2007; 4: S9-S11.
58. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-76.
59. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-32.
60. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
61. Drury P on behalf of the FIELD Study Investigators. Mild renal impairment and cardiovascular outcomes in type 2 diabetes: Results from the FIELD study. Diabetologia 2006; 49(Suppl 1): 6-7.
62. Edwards MS, Wilson DB, Craven TE, Stafford J, Fried LF, Wong TY, et al. Associations between retinal microvascular abnormalities and declining renal function in the elderly population: The Cardiovascular Health Study. Am J Kidney Dis 2005; 46: 214-24.
63. Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Rev 1999; 7: 245-52.
64. Ziegler D, Rathmann W, Haastert B, Füchsle-Reiter A, Löwel H, Mielck A. Prevalence of polyneuropathy in impaired glucose tolerance and diabetes. The MONICA/KORA Augsburg Surveys and Myocardial Infarction Registry (KORA-A Study). Diabetologia 2005; 48: A364-5.
65. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia 2000; 43: 957-73.
66. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003; 26: 1790-5.
67. Aulivola B, Hile CN, Hamdan AD, Sheahan MG, Veraldi JR, Skillman JJ, et al. Major lower extremity amputation: Outcome of a modern series. Arch Surg 2004; 139: 395-9.
68. The Diabetes Control and Complication Trial Research Group. The absence of glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-98.
69. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
70. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
71. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
72. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
73. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008; 358: 2560-72.
74. Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORDEYE). Am J Cardiol 2007; 99: [suppl]103i-111i.
75. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004; 122: 1631-40.
76. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-97.
77. Xu J, Lee ET, Devereux RB, Umans JG, Bella JN, Shara NM, et al. A longitudinal study of risk factors for incident albuminuria in diabetic American Indians: The Strong Heart Study. Am J Kidney Dis 2008; 51: 415-24.
78. Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, Klein RL. Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004; 10: 3395-418.
79. Earle KA, Harry D, Zitouni K. Circulating cholesterol as a modulator of risk for renal injury in patients with type 2 diabetes. Diabetes Res Clin Pract 2008; 79: 68-73.
80. Van Hecke MV, Dekker JM, Nijpels G, Teerlink T, Jakobs C, Stolk RP, et al. Homocysteine, S-adenosylmethionine and S-adenosylhomocysteine are associated with retinal microvascular abnormalities: The Hoorn Study. Clin Sci (Lond) 2008; 114: 479-87.
81. Fosmark DA, Torjesen PA, Kilhovd BK, Berg TJ, Sandvik L, Hanssen KF, et al. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 2006; 55: 232-6.
82. The Metascreen Writing Committee. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes. Diabetes Care 2006; 29: 2701-7.
83. Olsen BS, Sjølie AK, Hougaard P, Johannesen J, Marinelli K, Jacobsen BB, Mortensen HB; Danish Study Group of Diabetes in Childhood. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complicat 2004; 18: 160-4.
84. Monti MC, Lonsdale JT, Montomoli C, Montross R, Schlag E, Greenberg DA. Familial risk factors for microvascular complications and differential male-female risk in a large cohort of american families with Type 1 diabetes. J Clin Endocrinol Metab 2007; 92: 4650-5.
85. Fava S, Hattersley AT. The role of genetic susceptibility in diabetic nephropathy: Evidence from family studies. Nephrol Dial Transplant 2002; 17: 1543-6.
86. Tong Z, Yang Z, Patel S, Chen H, Gibbs D, Yang X, et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci USA 2008; 105: 6998-7003.
87. Porta M, Sjoelie AK, Chaturvedi N, Stevens L, Rottiers R, Veglio M, et al. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 2001; 44: 2203-9.
88. Levin SR, Coburn JW, Abraira C, Henderson WG, Colwell JA, Emanuele NV, et al. Effect of intensive glycemic control on micro-albuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000; 23: 1478-85.
89. Adler A. Risk factors for diabetic neuropathy and foot ulceration. Curr Diabetes Rep 2001; 1: 202-7.
90. Yamada T, Komatsu M, Komiya I, Miyahara Y, Shima Y, Matsuzaki M, et al. Development, progression, and regression of micro-albuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control: The Kashiwa study. Diabetes Care 2005; 28: 2733-8.
91. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-50.
92. Bleyer AJ, Sedor JR, Freedman BI, O'Brien A, Russell GB, Graley J, Schelling JR. Risk factors for development and progression of diabetic kidney disease and treatment patterns among diabetic siblings of patients with diabetic kidney disease. Am J Kidney Dis 2008; 51: 29-37.
93. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347: 797-805.
94. Abdul-Ghani M, Nawaf G, Nawaf F, Itzhak B, Minuchin O, Vardi P. Increased prevalence of microvascular complications in type 2 diabetes patients with the metabolic syndrome. Isr Med Assoc J 2006; 8: 378-82.
95. van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Blood pressure, lipids, and obesity are associated with retinopathy: The Hoorn study. Diabetes Care 2002; 25: 1320-5.
96. Dorchy H, Claes C, Verougstraete C. Risk factors of developing proliferative retinopathy in type 1 diabetic patients: Role of BMI. Diabetes Care 2003; 25: 798-9.
97. Muhlhauser I, Bender R, Bott U, Jorgens V, Grusser M, Wagener W, et al. Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes. Diabetes Med 1996; 13: 536-43.
98. Eliasson B. Cigarette smoking and diabetes. Prog Cardiovasc Dis 2003; 45: 405-13.
99. Chuahirun T, Khanna A, Kimball K, Wesson DE. Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes. Am J Kidney Dis 2003; 41: 13-21.
100. Havel E, Rencoval J, Novak L, Blaha V, Solichova D, Bratova M, et al. Serum lipoproteins lowering and diabetic exudative retinopathy. Atherosclerosis 1997; 134: 309-12.
101. Tershakovec AM, Keane WF, Zhang Z, Lyle PA, Appel GB, McGill JB, et al. Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study. Diabetes Care 2008; 31: 445-7.
102. Looker HC, Fagot-Campagna A, Gunter EW, Pfeiffer CM, Venkat Narayan KM, Knowler WC, et al. Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes. Diabetologia 2003; 46: 766-72.
103. Chaturvedi N, Schalkwijk CG, Abrahamian H, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Circulating and urinary transforming growth factor beta1, Amadori albumin, and complications of type 1 diabetes: The EURODIAB prospective complications study. Diabetes Care 2002; 25: 2320-7.
104. Bhanuprakash Reddy G, Satyanarayana A, Balakrishna N, Radha Ayyagari M, Padma K Viswanath J, et al. Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy. Mol Vis 2008; 14: 593-601.
105. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102: 520-6.
106. Keenan HA, Costacou T, Sun JK, Doria A, Cavellerano J, Coney J, et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: The 50-year medalist study. Diabetes Care 2007; 30: 1995-7.
107. Kancaronkováa K, Muzcaroníka J, Karáskováb J, Beráneka M, Hájeka D, Znojila V, et al. Duration of non-insulin-dependent diabetes mellitus and the TNF-beta NcoI genotype as predictive factors in proliferative diabetic retinopathy. Ophthalmologica 2001; 215: 294-8.
108. Petrovič MG, Peterlin B, Hawlina M, Petrovič D. Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in Caucasians. J diabetes Complicat 2005; 19: 70-3.
109. Maeda M, Yamamoto I, Fukuda M, Motomura T, Nishida M, None S, et al. MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese type 2 diabetic patients. J Diabetes Complicat 2008; 22: 119-25.
110. Izmajlowicz ML, Groves C, Horton V, Owen R, Stratton I, Turner RC, et al. Genetic predisposition to vascular complications of diabetes. Diabetologia 1998; 41: Suppl 1: A353.
111. Emanuele N, Sacks J, Klein R, Reda D, Anderson R, Duckworth W, et al. Ethnicity, race, and baseline retinopathy correlates in the Veterans Affairs Diabetes Trial. Diabetes Care 2005; 28: 1954-8.
112. Ferris FL, Chew EY, Hoogwerf BJ. Serum lipids and diabetic retinopathy. Diabetes Care 1996; 19: 1291-3.
113. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. ETDRS Report 22. Arch Ophthalmol 1996; 114: 1079-84.
114. Ucgun NI, Yildirim Z, Kilic N, Gursel E. The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients. Ann NY Acad Sci 2007; 100: 213-7.
115. Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC. The role of serum lipids in exudative diabetic maculopathy: Is there a place for lipid-lowering therapy? Eye 2002; 16: 689-93.
116. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss. Early Treatment Diabetic Retinopathy Study Report 18. Invest Ophthalmol Vis Sci 1998; 39: 233-52.
117. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Ellis D, LaPorte RE, et al. Factors associated with avoidance of severe complications after 25 yr of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 1990; 13: 741-7.
118. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, Klein RL. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/ EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910-8.
119. Turczyński B, Michalska-Małecka K, Słowińska L, Szczesny S, Romaniuk W. Correlations between the severity of retinopathy in diabetic patients and whole blood and plasma viscosity. Clin Hemorheol Microcirc 2003; 29: 129-37.
120. Fujisawa T, Ikegami H, Yamato E, Kawaguchi Y, Ueda H, Shintani M, et al. Association of plasma fibrinogen level and blood pressure with diabetic retinopathy, and renal complications associated with proliferative diabetic retinopathy, in Type 2 diabetes mellitus. Diabetes Med 1999; 16: 522-6.
121. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes. UK Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-9.
122. Hadjadj S, Duly-Bouhanick B, Bekherraz A, Bridoux F, Gallois Y, Mauco G, et al. Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab 2004; 30: 43-51.
123. Cusick M, Chew EY, Hoogwerf B, Agrón E, Wu L, Lindley A, et al. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS). ETDRS 26. Kidney Int 2004; 66: 1173-9.
124. Smulders Y, Rakic M, Stehouwer C, Weijers RN, Slaats EH, Silberbusch J. Determinants of progression of microalbuminuria in patients with NIDDM: a prospective study. Diabetes Care 1997; 20: 999-1005.
125. Cardoso CR, Salles GF Predictors of development and progression of microvascular complications in a cohort of Brazilian type 2 diabetic patients. J Diabetes Complic 2008; 22: 164-70.
126. Harrold BP, Marmion VJ, Gough KR. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 1969; 18: 285-91.
127. Cullen JF, Ireland JT and Oliver MF. A controlled trial of Atromid therapy in exudative diabetic retinopathy. Trans Ophth Soc UK 1964; 84: 281.
128. Duncan LJ, Cullen JF, Ireland JT, Nolan J, Clarke BF, Oliver MF. A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes 1968; 17: 458-67.
129. Dorne PA. Exudative diabetic retinopathy. The use of clofibrate in the treatment of hard exudates using a reduced but prolonged dosage over several years Arch Ophtalmol (Paris) 1977; 37: 393-400. [Article in French]
130. Freyberger H, Schifferdecker E, Schatz H. Regression of hard exudates in diabetic background retinopathy in therapy with etiofibrate antilipemic agent. Med Klin 1994; 89: 594-97 [Article in German].
131. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 2001; 59: 260-9.
132. Fried LF. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 2008; 74: 571-6
133. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Fibrate-associated adverse effects beyond muscle and liver toxicity. Curr Pharm Des 2008; 14: 574-87.
134. Ansquer JC, Foucher C, Rattier S, Taskinen M-R, Steiner G for the DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45: 485-93.
135. Kasumi T, Hirano T, Yoshino G for the fenofibrate study group: Effects of fenofibrate on albuminuria in participants with hypertriglyceridemia and/or hyperuricemia: A multicenter, randomised, double-blind, placebo-controlled, crossover study. Curr Ther Res Clin Exp 2003; 64: 434-46.
136. Smulders YM, van Eeden AE, Stehouwer CD, Weijers RN, Slaats EH, Silberbusch J. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 1997; 27: 997-1002.
137. Berenyi MR, Straus B, Miglietta OE. Treatment of diabetic neuropathy with clofibrate. J Am Geriatr Soc 1971; 19: 763-72.
138. Corrao G, Zambon A, Bert L, Botteri E, Leoni O, Contiero P. Lipid lowering drugs prescription and the risk of peripheral neuropathy: An exploratory case-control study using automated databases. J Epidemiol Commun Health 2004; 58: 1047-51.
139. Davis TME, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: The Fremantle Diabetes Study. Diabetologia 2008; 51: 562-6.
140. The FIELD Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: The rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovasc Diabetol 2004: 3: 9.
141. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350: 48-58.
142. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, Mikhailidis DP, Elisaf MS. Fenofibrate: Metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005; 3: 87-98.
143. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18: 1450-2.
144. Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM. Leukocytes in diabetic retinopathy. Curr Diabetes Rev 2007; 3: 3-14.
145. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007; 95: 103.
146. Joussen AM, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand SJ, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 2002; 160: 501-9.
147. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye 2006; 20: 1366-9.
148. Kim J, Ahn JH, Kim JH, Yu YS, Kim HS, Ha J, et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 2007; 84: 886-93.
149. Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci 2008; 82: 884-91.
150. Skrha J, Stulc T, Hilgertová J, Weiserová H, Kvasnicka J, Ceska R. Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. Eur J Pharmacol 2004; 493: 183-9.
151. Losada M, Alio JL. Malondialdehyde serum concentration in type 1 diabetic with and without retinopathy. Doc Ophthalmol 1996-1997; 93: 223-9.
152. Chen XR, Besson VC, Palmier B, Garcia Y, Plotkine M, Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma 2007; 24: 1119-31.
153. Chen L, Zhang J, Zhang Y, Wang Y, Wang B. Improvement of inflammatory responses associated with NF-kappaB pathway in kidneys from diabetic rats. Inflamm Res 2008; 57(5): 199-204.
154. Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, et al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 2006; 69: 1511-7.
155. Zhao X, Li LY.PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. Am J Nephrol 2008; 28: 598-606.
156. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Fibrate-associated adverse effects beyond muscle and liver toxicity. Curr Pharm Des 2008; 14(6): 574-87.
157. Huber JD. Diabetes, cognitive function, and the blood-brain barrier. Curr Pharm Des 2008; 14(16): 1594-600.
158. Yamagishi S, Ueda S, Matsui T, Nakamura K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr Pharm Des 2008; 14(10): 962-8.